KMT2A and acute myeloid leukemia: To rule out that the tumor suppressive effect of RBM25 was restricted to the Lp30 AML model, we carried out an in vitro competitive (GFP/YFP) assay using a murine MLL-AF9 fusion-driven AML model22.